Therefore we assessed the expression levels of several known REV-ERB target genes involved in hyperlipidemia (Dhcr24, ApoE, and ApoC3) by QPCR and observed a significant decrease in these genes (S2 Fig) suggesting that SR9009 activation of REV-ERB is suppressing cholesterol and lipid metabolism but may not have efficacy in this model in which treatment started well after the development of NASH began. Here, DHCR24 is linked to metabolic dysfunction-associated steatohepatitis.